Skip to main content

Table 3 Hazard ratios of overall survival for several basic characteristics by breast cancer subtyping

From: Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival

    Molecular subtyping
  All        Five subtypes Four subtypes
Variables (N = 951) IHC-Luminal A
(N = 486)
IHC-Luminal B
(N = 123)
IHC-HER2
(N = 113)
IHC-BLBC
(N = 139)
IHC-QNBC/5NP
(N = 90)
IHC-TNBC
(N = 229)
  HR(N of event) HR(N of event) HR(N of event) HR(N of event) HR(N of event) HR(N of event) HR(N of event)
  (95%CI) p-value (95%CI) p-value (95%CI) p-value (95%CI) p-value (95%CI) p-value (95%CI) p-value (95%CI) p-value
Age Group (yr)               
   < 50 1.00(85/590)   1.00(22/297)   1.00(14/87)   1.00(21/51)   1.00(17/97)   1.00(11/58)   1.00(28/155)  
   ≥ 50 0.99(52/361)   1.43(20/189)   1.42(8/36)   0.32(9/62)   0.92(7/42)   1.23(8/32)   1.08(15/74)  
  (0.70-1.39) 0.96 (0.78-2.61) 1.0 (0.59-3.37) 1.0 (0.15-0.71) 0.04 (0.38-2.20) 1.0 (0.49-3.04) 1.0 (0.58-2.03) 1.0
Tumor size (cm)               
   ≤ 2 cm 1.00(28/392) 0.005 1.00(7/228)   1.00(5/39)   1.00(6/35)   1.00(6/52)   1.00(4/38)   1.00(10/90)  
   2-5 cm 2.61(87/493)   4.21(30/231)   1.29(14/75)   1.93(19/64)   1.36(12/76)   2.78(12/47)   1.86(24/123)  
  (1.70-4.00) < 0.001 (1.94-10.1) 0.001 (0.46-3.61) 1.0 (0.77-4.83) 1.0 (0.51-3.64) 0.65 (0.89-8.63) 0.62 (0.88-3.88) 0.010
   > 5cm 5.34(22/66)   6.55(5/27)   2.17(3/9)   2.46(5/14)   6.65(6/11)   7.76(3/5)   7.54(9/16)  
  (3.05-9.33) < 0.001 (2.08-20.6) 0.008 (0.51-9.16) 1.0 (0.75-8.08) 1.0 (2.13-20.3) 0.008 (1.73-34.5) 0.046 (3.12-18.2) < 0.001
LN involvement               
   Negative 1.00(39/498)   1.00(7/246)   1.00(7/52)   1.00(12/63)   1.00(8/89)   1.00(5/48)   1.00(13/137)  
   Positive 2.93(98/453)   4.88(35/240)   1.55(15/71)   2.23(18/50)   4.6(16/50)   3.96(14/42)   3.99(30/92)  
  (2.03-4.24) < 0.001 (2.25-10.45) < 0.001 (0.63-3.81) 1.0 (1.07-4.62) 0.26 (1.73-9.49) 0.004 (1.43-11.0) 0.064 (2.09-7.35) < 0.001
AJCC stage               
   I 1.00(10/254)   1.00(0/148)   1.00(2/19)   1.00(3/22)   1.00(2/38)   1.00(3/27)   1.00(5/65)  
   II 3.29(58/467)   NA*(21/221)   1.09(10/69)   1.70(13/57)   2.74(11/78)   0.72(3/42)   1.58(14/120)  
  (1.68-6.43) 0.001    (0.23-5.01) 1.0 (0.48-5.97) 1.0 (0.61-12.3) 1.0 (0.14-3.58) 1.0 (0.57-4.40) 1.0
   III 8.74(69/230)   NA*(21/117)   2.60(10/35)   3.53(14/34)   11.36(11/23)   7.85(13/21)   9.16(24/44)  
  (4.50-16.9) < 0.001    (0.57-11.9) 1.0 (1.01-12.34) 0.37 (2.57-51.3) 0.016 (2.23-27.5) 0.005 (3.49-24.0) < 0.001
Adjuvant chemotherapy               
   Not done 1.00(35/155)   1.00(12/95)   1.00(9/20)   1.00(7/22)   1.00(6/10)   1.00(1/8)   1.00(7/18)  
   Done 0.59(102/796)   0.74(30/391)   0.23(13/103)   0.75(23/91)   0.17(18/129)   2.23(18/82)   0.41(36/211)  
  (0.40-0.87) 0.008 (0.37-1.45) 1.0 (0.09-0.52) 0.007 (0.32-1.74) 1.0 (0.07-0.43) < 0.001 (0.29-16.7) 1.0 (0.18-0.93) 0.06
  1. * There is no event in AJCC stage I of luminal A subtype.
  2. IHC: immunohistochemistry, LN: lymph node